ENTA - Enanta Pharmaceuticals, Inc. -  [ ]

Ticker Details
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach & drug discovery capabilities to develop its products.
IPO Date: March 21, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $379.76M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.90 | 2.40%
Avg Daily Range (30 D): $0.40 | 3.01%
Avg Daily Range (90 D): $0.37 | 2.81%
Institutional Daily Volume
Avg Daily Volume: .2M
Avg Daily Volume (30 D): .15M
Avg Daily Volume (90 D): .14M
Trade Size
Avg Trade Size (Sh.): 72
Avg Trade Size (Sh.) (30 D): 49
Avg Trade Size (Sh.) (90 D): 50
Institutional Trades
Total Institutional Trades: 2,654
Avg Institutional Trade: $1.77M
Avg Institutional Trade (30 D): $1.61M
Avg Institutional Trade (90 D): $1.11M
Avg Institutional Trade Volume: .04M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.91M
Avg Closing Trade (30 D): $2.62M
Avg Closing Trade (90 D): $1.35M
Avg Closing Volume: 39.69K
 
News
Sep 29, 2025 @ 5:35 PM
10 Health Care Stocks With Whale Alerts In Today's...
Source: Benzinga Staff Writer
Sep 29, 2025 @ 5:28 PM
Enanta's RSV Pill Shows Promise In Cutting Recover...
Source: Vandana Singh
Sep 29, 2025 @ 5:06 PM
12 Health Care Stocks Moving In Monday's Intraday ...
Source: Benzinga Staff Writer
Sep 26, 2025 @ 9:06 PM
12 Health Care Stocks Moving In Friday's After-Mar...
Source: Benzinga Staff Writer
Jun 11, 2025 @ 9:07 PM
FDA Expands AbbVie's Mavyret Label To Include Acut...
Source: Vandana Singh
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-2.6 $-.45 $-.42
Diluted EPS $-2.6 $-.45 $-.42
Revenue $69.21M $17.16M $18.62M
Gross Profit
Net Income / Loss $-61.98M $-13.09M $-11.94M
Operating Income / Loss $-60.38M $-11.85M $-11.25M
Cost of Revenue
Net Cash Flow $-25.29M $-2.51M $5.14M
PE Ratio